- Home
- JL vs CHRO Comparison
JL vs CHRO Comparison
Compare JL & CHRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JL
- CHRO
- Stock Information
- Founded
- JL 1985
- CHRO 2002
- Country
- JL Hong Kong
- CHRO United States
- Employees
- JL N/A
- CHRO N/A
- Industry
- JL
- CHRO
- Sector
- JL
- CHRO
- Exchange
- JL NYSE
- CHRO Nasdaq
- Market Cap
- JL 10.0M
- CHRO 8.4M
- IPO Year
- JL 2024
- CHRO 2024
- Fundamental
- Price
- JL $3.90
- CHRO $0.95
- Analyst Decision
- JL
- CHRO Strong Buy
- Analyst Count
- JL 0
- CHRO 1
- Target Price
- JL N/A
- CHRO N/A
- AVG Volume (30 Days)
- JL 19.2K
- CHRO 2.1M
- Earning Date
- JL 05-23-2025
- CHRO 05-13-2025
- Dividend Yield
- JL N/A
- CHRO N/A
- EPS Growth
- JL N/A
- CHRO N/A
- EPS
- JL 0.54
- CHRO N/A
- Revenue
- JL $32,831,195.00
- CHRO N/A
- Revenue This Year
- JL N/A
- CHRO N/A
- Revenue Next Year
- JL N/A
- CHRO N/A
- P/E Ratio
- JL $7.55
- CHRO N/A
- Revenue Growth
- JL 7.72
- CHRO N/A
- 52 Week Low
- JL $0.23
- CHRO $0.45
- 52 Week High
- JL $13.41
- CHRO $3.80
- Technical
- Relative Strength Index (RSI)
- JL 61.21
- CHRO 35.68
- Support Level
- JL $3.10
- CHRO $0.91
- Resistance Level
- JL $4.20
- CHRO $1.14
- Average True Range (ATR)
- JL 0.24
- CHRO 0.12
- MACD
- JL 0.12
- CHRO -0.01
- Stochastic Oscillator
- JL 74.96
- CHRO 17.04
About JL J-LONG GROUP LIMITED
J-Long Group Ltd is an established distributor in Hong Kong of reflective and non-reflective garment trims including, among others, heat transfers, fabrics, woven labels and tapes, sewing badges, piping, zipper pullers and drawcords. It also offers a wide range of apparel solution services to cater to its customers' needs for reflective and non-reflective garment trims, ranging from market trend analysis, product design and development and production to quality control.
About CHRO Chromocell Therapeutics Corporation
Channel Therapeutics Corp is a clinical-stage biotechnology company developing and commercializing novel, non-opioid, non-addictive therapeutics to alleviate pain. The initial clinical focus is to selectively target the sodium ion channel known as NaV1.7 for the treatment of various types of chronic, visceral pain, acute and chronic eye pain, and post-surgical nerve blocks. Its pipeline includes CC8464 for ISFN and EM and CT2000 for Acute and CHronic Eye Pain-Dry Eye Disease.